Dr. Lucy Norris

• Ismail SK, Norris L, Higgins JR, Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis, British Journal of Haematology, 2015, pdoi: 10.1111/bjh.13521.Journal Article, 2015, URL
• Abu Saadeh, F, Langhe R, Galvin DM, O Toole SA, O'Donnell DM, Gleeson N, Norris LA, Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. , Thrombosis Research, 139, 2016, p135 - 141Journal Article, 2016, DOI
• Petch S, Norris L, O'Toole S, Gleeson N, Abu Saadeh F., Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice, Thrombosis Research, 145, 2016, p126 - 128Journal Article, 2016, DOI
• Siti K. Ismail, Lucy Norris, Ali Khashan, Nigel Simpson, Gustaaf Dekker, Jenny Myers, Lesley McCowan, Louise Kenny, John R. Higgins, [174-POS], Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 5, (1), 2015, p89--90Journal Article, 2015
• Lynne Kelly, Shanthi Muttukrishna, Lucy Norris, John Higgins, P10. Placental expression of haemostatic and angiogenic markers in preeclampsia, Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 1, (3-4), 2011, p277Journal Article, 2011
• Lucy A. Norris, Jeanette Brosnan, John Bonnar, Jacqueline Conard, Cornelius Kluft, Margareta Hellgren, Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone, Thromb Haemost, 2008Journal Article, 2008
• Skouby, S.O., Jespersen, J., Kluft, C., Lowe, G.D.O., Norris, L., Stevenson, J., Samsioe, G., The European Consensus Development Conference 2002: Sex steroids and cardiovascular diseases: On the route to combined evidence from OC and HRT/ERT, Maturitas, 44, (1), 2003, p69-82Journal Article, 2003
• Out, H.J., Jespersen, J., Pabinger, I., MacRae, K., Crosignani, P., Skouby, S.O., Winkler, U.H., Norris, L., Gaspard, U., David, Van Enk, A., Van De Ende, A., Mishell, D., Voncken, D., Klipping, C., Sidelmann, J., The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomized multicenter study, Contraception, 67, (3), 2003, p173-185Journal Article, 2003
• Skouby, S.O., Jespersen, J., Kluft, C., Lowe, G.D.O., Norris, L., Samsioe, G., Stevenson, J., On the route to combined evidence from OC and HRT/ERT, European Journal of Contraception and Reproductive Health Care, 7, (4), 2002, p185-198Journal Article, 2002
• John R Higgins, John Bonnar, Lucy A Norris, Michael R.N Darling, Joseph J Walshe, The Effect of Pre-eclampsia on Coagulation and Fibrinolytic Activation in the Neonate, Thrombosis Research, 99, (6), 2000, p567--570Journal Article, 2000
• Winkler, U.H., Norris, L., Gaspard, U., Van Enk, A., Mishell, D., Voncken, D., Klipping, C., An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables: Outline of the protocol, Contraception, 59, (6), 1999, p345-355Journal Article, 1999
• Lucy A. Norris, John Bonnar, 9 Haemostatic changes and the oral contraceptive pill, Baillière's Clinical Obstetrics and Gynaecology, 11, (3), 1997, p545--564Journal Article, 1997
• Wu, J.J., Yakoob, J., Norris, L.A., Keeling, P.W.N., Is the fertile period reduced in patients with inflammatory bowel disease? Short report, Irish Journal of Medical Science, 165, (1), 1996, p35-36Journal Article, 1996
• Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G, Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study, Thrombosis and Haemostasis, 92, (4), 2004, p791 - 796Journal Article, 2004
• Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J, Tinzaparin sodium for thrombosis treatment and prevention during pregnancy., American Journal of Obstetrics and Gynaecology, 190, (4), 2004, p495 - 501Journal Article, 2004
• Norris, Blood Coagulation (invited review), Best Practice Research in Clinical Obstetrics and Gynaecol, 17, (3), 2003, p369 - 383Journal Article, 2003
• Skouby SO, Jespersen J, Kluft C, Lowe GD, Norris L Samsoie G, Stevenson J. Writing group for the 3rd European Conference on Sex Steroids and Cardiovascular disease, On the route to combined evidence from OC and HRT/ERT, European Journal of Contraceptive Reproductive Health Care, 7, (4), 2002, p185 - 198Journal Article, 2002
• Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J., Haemostatic risk factors in healthy post menopausal women taking hormone replacement therapy, Maturitas, 43, (2), 2002, p125 - 133Journal Article, 2002
• Yoneda M, Brosnan JF, Norris LA, Bonnar J, The effect of LMWH (Tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis, Thrombosis Research, 117, 2006, p283 - 290Journal Article, 2006
• Petch S, Norris LA, O'Toole SA, Gleeson N, Saadeh FA, OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice., 2016Journal Article, 2016
• Martin F, Long JC, O'Toole SA, O'Leary JJ, Abu Saadeh F, Gleeson N, Norris LA, Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2016, 140, (Supplement 1), 2016, ppS181 - S181Published Abstract, 2016, DOI
• Norris LA, Martin FA, O'Toole SA, Saadeh FA, Gleeson N, PO-24 - Determinants of thrombin generation in gynaecological malignancies., 2016Published Abstract, 2016, DOI
• Higgins JR, Bonnar J, Norris LA, Darling MR, Walshe JJ, The effect of pre-eclampsia on coagulation and fibrinolytic activation in the neonate, Thrombosis Research, 99, (6), 2000, p567 - 570Journal Article, 2000
• Bonnar J, Green R, Norris L, Perinatal aspects of inherited thrombophilia, Seminars in Thrombosis and Haemostasis, 25, (5), 1999, p481 - 485Journal Article, 1999
• Bonnar J, Norris LA, Green R, Low molecular weight heparin for thromboprophylaxis during caesarean section, Thrombosis Research, 96, (4), 1999, p317 - 322Journal Article, 1999
• Wen Y, Killalea S, Norris LA, Cooke T, Feely J, Vitamin E suplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation, European Journal of Clinical Investigation, 29, (12), 1999, p1027 - 1034Journal Article, 1999
• Norris LA, Nitric Oxide in the Uteroplacental, fetoplacental and peripheral circulations in pre-eclampsia, Obstetrics and Gynaecology, 93, (6), 1999, p958 - 963Journal Article, 1999
• Wen Y, Doyle MC, Norris LA, Sinnot, MM, Cooke T, Harrison RF, Feely J, Combined oestrogen-progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in post menopausal women, British Journal of Clinical Pharmacol, 47, (3), 1999, p315 - 321Journal Article, 1999
• Bonnar J, Green R, Norris L, Inherited thrombophilia and pregnancy: the obstetric perspective, Seminars in Thrombosis and Haemostasis, 24, (Suppl (1)), 1998, p49 - 53Journal Article, 1998
• Higgins JR, Walshe JJ, Darling MR, Norris L, Bonnar J, Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies, American Journal of Obstetrics and Gynaecology, 179, (2), 1998, p520 - 526Journal Article, 1998
• Adebayo GI, Norris L, Devitt M, Bonnar J, Feely J, Effects of oral contraceptive containing different progestogens on sodium lithium countertransport in normal females, Journal of Human Hypertension, 12, (4), 1998, p235 - 238Journal Article, 1998
• Norris LA, Bonnar J, Haemostatic changes and the oral contaceptive pill, Ballieres Clinics in Obstetrics and Gynaecology, 11, (3), 1997, p545 - 564Journal Article, 1997
• Norris LA, Bonnar J, The effect of oestrogen dose and progestogen type on haemostatic changes in women taking oral contraceptives, British Journal of Obstetrics and Gynaecology, 103, (3), 1996, p261 - 267Journal Article, 1996
• Comparative assessment of haemostatic variables with focus on levonorgestrel in, editor(s)Teichman AT, Corbin A , Levonorgestrel, Berlin, George Theime Verlag, 1998, pp39 - 46, [Bonnar J, Norris LA, Sheppard BL]Book Chapter, 1998
• The Oral Contraceptive and Hemostasis Study Group, An open label randomised study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables, Contraception, 59, 1999, p345 - 355Journal Article, 1999
• Oral Contraceptive and Hemostasis Study Group, The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large multicentre study, Contraception, 67, (3), 2003, p173 - 185Journal Article, 2003
• Wu J, Norris LA, Wen JC, Sheppard BL, Feely J, Bonnar J, The effect of hormone replacement therapy on plasma vitamin E levels in post menopausal women, European Journal of Obstetrics Gynaecology and reproductive biology, 66, (2), 1996, p151 - 154Journal Article, 1996
• Norris LA, Devitt M, Bonnar J, The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users, Thrombosis research, 81, (4), 1996, p407 - 417Journal Article, 1996
• Wu JJ, Yakoob J, Norris LA, Keeling PW, Is the fertile period reduced in patients with inflammatory bowel disease, Irish Journal of Medical Science, 165, (1), 1996, p35 - 36Journal Article, 1996
• Norris LA, Bonnar J, Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives, Thrombosis and Haemostasis, 72, (6), 1994, p926 - 930Journal Article, 1994
• Norris LA, Bonnar J, The in vitro effect of aspirin on increased whole blood platelet aggregation in oral contraceptive users, Thrombosis Research, 74, (1), 1994, p309 - 315Journal Article, 1994
• Norris LA, Sheppard BL, Burke G, Bonnar J, Platelet activation in normotensive and hypertensive pregnancies complicated by intra-uterine growth retardation, British Journal of Obstetrics and Gynaecology, 101, (3), 1994, p209 - 214Journal Article, 1994
• Norris LA, Gleeson N, Sheppard BL, Bonnar J, Whole blood platelet aggregation in moderate and severe pre-eclampsia, British Journal of Obstetrics and Gynaecology, 100, (7), 1993, p684 - 688Journal Article, 1993
• Norris LA, Sheppard BL, Bonnar J, Increased whole blood platelet aggregation in normal pregnancy can be prevented in vitro by aspirin and dazmegerel (UK38485), British Journal of Obstetrics and Gynaecology, 99, (3), 1992, p253 - 257Journal Article, 1992
• Norris LA, Platelet activation in pregnancy and oral contraception, Trinity College Dublin, 1992Thesis, 1992
• Bloemenkamp K, Hannaford P, Helmerhorst F, Jespersen J, Kluft C, Norris L, Skouby S (Writing Group) , Consensus statement: Combined oral contraceptives and cardiovascular disease, Gynecological Endocrinology, 10 , (Supplement 2), 1996, p119 - 121Journal Article, 1996
• Norris LA, Bonnar J, Estrogen dose and progestogen type: their effect on hemostatic changes in oral contraceptive users, Gynecological Endocrinolgy, 10, (Supplement 2), 1996, p119 - 121Journal Article, 1996
• Norris LA, Sex steroids and changes in the cardiovascular system I: Change in systems relevant to the development of cardiovascular disease- Annotation of Esbjerg I consensus meeting., Combined oral contraceptives and cardiovascular disease: Consensus Development meeting, Amsterdam , November , 1995, Published in Gynecological Endocrinology 1996;10: 25-27Invited Talk, 1995
• Norris LA, Bonnar J, Increased whole blood aggregation in oral contraceptive users can be prevented in vitro by a thromboxane sythetase inhibitor, Gynecological Endocrinology, 10, (Supplement 2), 1996, p119 - 121Journal Article, 1996
• Norris LA, Bonnar J, New low dose oral contraceptives: less thrombotic risk, Modern medicine, 25, (9), 1995, p27 - 30Journal Article, 1995
• Norris LA, Bonnar J, New low dose oral contraceptives: less thrombotic risk?, Modern medicine, 25, (9), 1995, p27 - 30Journal Article, 1995
• C. Spourquet, M.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris., Expression of Coagulation Proteases from the Activated Protein C Pathway in Ovarian Tumours, Research Practice in Thrombosis and Haemostasis , ISTH, Berlin, July 2017, 1, (1), Wiley, 2017, pp630 - 630Published Abstract, 2017, DOI
• M.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris ., The Effect of Neoadjuvant Chemotherapy on the Activated Protein C (aPC) Pathway in High Grade Serous Ovarian Cancer Patients., Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis , Berlin, July 2017, 1, (1), Wiley, 2017, pp625 - 625Published Abstract, 2017, DOI
• Thompson C, McCormick C, Kamran W, O'Riain C, Norris L, Gallagher D, Gleeson N., Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes, Irish Journal of Medical Science, 2018Journal Article, 2018, DOI
• Thompson C, Kamran W, Dockrell L, Khalid S, Kumari M, Ibrahim N, OʼLeary J, Norris L, Petzold M, OʼToole S, Gleeson N, The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma, International Journal of Gynaecological Cancer, 28, (6), 2018, p1066 - 1072Journal Article, 2018, DOI
• LA Norris, F Abu Saadeh, M Ward, SA O'Toole, Z Marchocki, N. Ibrahim, N Gleeson, Development and validation of a risk model for prediction of venous thromboembolism in gynaecological cancer patients, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), Elsevier, 2018, ppS183 - S184Oral Presentation, 2018, DOI
• Z. Marchocki, N. Gleeson, F. Abu Saadeh, M.P. Ward, S.A. O'Toole, L.A. Norris, Fibrinogen, D-Dimers and thrombin generation assays as predictors of the risk of recurrent VTE in patients with gynaecological malignancies, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), 2018, pp200 - 200Meeting Abstract, 2018, DOI
• Z. Marchocki, L.N. Norris, S.A. O'Toole, N. Gleeson, F. Abu Saadeh S235, Patients experience and compliance with extended LMWH prophylaxis post-surgery for gynaecological cancer, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), Elsevier, 2018, ppS235 - S235Published Abstract, 2018, DOI
• Marchocki Z, Abu Saadeh F, Gleeson N, Norris L, Risk of recurrence of venous thromboembolism in patients with gynaecological cancer, Thrombosis Research, Womens Issues in Thrombosis and Haemostasis, Barcelona, March 2017, 151, (Supplement 1), 2017, ppS133 - S133Published Abstract, 2017, DOI
• Thrombosis Research, (2008), Marc Rodger, Henri Versteeg, [Editorial board member]Journal, 2008
• Ward MP, Abu Saadeh, F, O'Toole S, Marchocki Z, Gleeson N, Norris LA, Optimisation of Thrombin Generation as a Predictive Biomarker for Venous Thromboembolism in Gynaecological Malignancies, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, Dublin, July 2018, 2, (Supplement 1), Wiley, 2018, ppPB518 - PB518Published Abstract, 2018, DOI
• Marchocki Z, Norris L, O'Toole S, Gleeson N, Abu Saadeh F, Patients' experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynaecological cancer. A prospective observational study, International Journal of Gynaecological Cancer. , 2019Journal Article, 2019, DOI
• Marchocki Z, Norris LA, , Abu Saadeh F, Gleeson N, Recurrence of Venous thromboembolism in gynaecological malignancies, incidence, risk factors and impact on survival, European Journal of Gynae Oncology , 40, (3), 2019, p413 - 419Journal Article, 2019, DOI
• S O'Toole, M Foley, S Rizmee, L Norris, W Kamran, N Ibrahim, M Ward, C Thompson, C Murphy, M Anglim, T D'Arcy, N Farah, H O'Connor, J O'Leary, F AbuSaadeh, N Gleeson, HE4 has a role in identifying high risk prognostic factors in endometrial cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA351 - A352Published Abstract, 2019
• B Mohamed, S O'Toole, S Elbaruni, L Norris, F AbuSaadeh, S Gray, J. O'Leary , EP926 PAD enzymes as a candidate therapeutic target in ovarian cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA497 - A497Published Abstract, 2019
• O'Toole S, Melarcode H, Elbaruni S, F AbuSaadeh, M Ward, M Gallagher, L Norris, S Gray, J O`Leary and B Mohamed., EP926 PAD enzymes as a candidate therapeutic target in ovarian cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA497 - A497Published Abstract, 2019
• Eilis Perez, Bashir Mohamed, Danny Di Capua, Noreen Gleeson, Claire Thompson, Feras Abu Saadeh, Cara Martin, Lucy Norris, Ciaran O'Riain, Mark Bates, Lorraine O'Driscoll, John O'Leary, Sharon O'Toole. , High Expression Of Neuromedin U In High Grade Serous Ovarian Cancer Confers A Progression Free Survival Advantage., Laboratory Investigation, 99, 2019, pp101 - 101Published Abstract, 2019
• Melad Saed, Sharon O'Toole, Lucy Norris, Steven Gray, Feras Abu Saadeh, John O'Leary, Bashir Mohamed. , The Efficacy Of Nanocomplexes Complexed With Specific Biomarker Targets In Ovarian Cancer Treatment, An Ex-Vivo Explant Case Study, Laboratory Investigation, 99, 2019, pp106 - 106Published Abstract, 2019
• Norris LA, Ward MP, O'Toole SA, Marchocki Z, Ibrahim N, Khashan AS, Abu Saadeh F, Gleeson N. , A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score. , Research Practice in Thrombosis and Haemostasis, 4, (5), 2020, p848 - 859Journal Article, 2020, DOI
• O'Toole SA, Huang Y, Norris L, Power Foley M, Shireen R, McDonald S, Kamran W, Ibrahim N, Ward M, Thompson C, Murphy C, D'Arcy T, Farah N, Heron E, O'Leary JJ, Abu Saadeh F, Gleeson N., HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status., Gynecologic oncology, 2021Journal Article, 2021, DOI
• Norris, Lucy A., Papadakis, Emmanouil S., A new journal in a brave new world, 1826, 2020, -Miscellaneous, 2020, DOI
• Ibrahim, Elzahra, Norris, Lucy A., Abu Saadeh, Feras, Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers, Thrombosis Update, 2, 2021, p100038Journal Article, 2021, DOI
• Ward, Mark P., Saadeh, Feras Abu, O'Toole, Sharon A., O'Leary, John J., Gleeson, Noreen, Norris, Lucy A., Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway, Thrombosis Research, 200, 2021, p91 - 98Journal Article, 2021, DOI
• McKendry, Kate, Duff, Stephen, Huang, Yanmei, Redha, Mostafa, Scanlon, Áine, Abu Saadeh, Feras, Gleeson, Noreen, O"Leary, John, Norris, Lucy, O"Toole, Sharon, The value of HE4, D"dimer, and fibrinogen compared to CA125 alone in triaging women presenting with pelvic masses: a retrospective cohort study, Acta Obstetricia et Gynecologica Scandinavica, 2021Journal Article, 2021, DOI
• Ward, M.P., Kane, L.E., Norris, L.A et al. , Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?, Molecular Cancer, 20, 2021, p59-Journal Article, 2021, DOI
• Spillane CD, Cooke NM, Ward MP, Kenny D, Blackshields G, Kelly T, Bates M, Huang Y, Martin C, Skehan S, Canney A, Gallagher M, Smyth P, Brady N, Clarke A, Mohamed B, Norris L, Brooks DA, Brooks RD, Heatlie JK, Selemidis S, Hanniffy S, Dixon E, Sheils O, O'Toole SA, O'Leary JJ., The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon., Translational oncology, 14, (12), 2021, p101229Journal Article, 2021, DOI
• Abu Saadeh F, Marchocki Z, O'Toole SA, Ibrahim N, Gleeson N, Norris LA., Extended thromboprophylaxis post gynaecological cancer surgery; the effect of weight adjusted and fixed dose LMWH (Tinzaparin)., Thrombosis Research, 207, 2021, p25 - 32Journal Article, 2021, DOI
• Papadakis E and Norris LA, Covid-19: "the end of the beginning", 1826, 2021, -Miscellaneous, 2021, DOI
• E Ibrahim, SA O'Toole, F Abu Saadeh, LA Norris., Lymph node status as a predictor of venous thromboembolic risk postoperatively in gynae-oncology. , International Journal of Gynecologic Cancer, European Society For Gynae-Oncology (ESGO), 31, (Supplement 3), 2021Conference Paper, 2021
• Ibrahim E, O'Toole S, Ward M, Abu Saadeh F, Norris LA. , Factor VIIIc predicts venous thromboembolism in gynaecological cancer patients., Research. Practice in Thrombosis. and Haemostasis , International Society for Thrombosis and Haemostasis, Philadelphia, July 2021, 5, (Supplement 2), Wiley, 2021, ppPB1096 - PB1096Conference Paper, 2021, URL
• Thrombosis Update, Elsevier, [Editor in Chief], 2019-2029Editorial Board, 2019
• Mark P Ward, Mark Bates, Bashir Mohamed, Tanya Kelly, Roisin O'Connor, Robert Brooks, Doug Brooks, Stavros Selemidis, Celine Ovaere, Jane Tully, Patrick Maguire, Catherine O'Gorman, Waseem Kamran, James Beirne, Feras Saadeh, Noreen Gleeson, Lucy Norris, Cara Martin, Sharon O'Toole, John O'Leary, Isolation and characterisation of circulating tumour cells from ovarian cancer patients, LABORATORY INVESTIGATION, March 2022, 102, (SUPPL 1), SPRINGER NATURE, 2022Poster, 2022, DOI
• Elzahra Ibrahim, Lucy Norris, Feras Abu Saadeh, Does the use of long-term Aspirin reduce risk of post operative VTE in Gynaecological cancer patients, International Journal of Gynecologic Cancer, 23rd ESGO, Berlin, Oct 2022, 32, 2022Poster, 2022, URL
• Mohamed BM, Ward MP, Bates M, Spillane CD, Kelly T, Martin C, Gallagher M, Heffernan S, Norris L, Kennedy J, Saadeh FA, Gleeson N, Brooks DA, Brooks RD, Selemidis S, O'Toole S, O'Leary JJ., Ex vivo expansion of circulating tumour cells (CTCs)., Scientific reports, 13, (1), 2023, p3704 - 3704Journal Article, 2023, DOI
• O'Neill AM, Calpin GG, Norris L, Beirne JP., The impact of enhanced recovery after gynaecological surgery: A systematic review and meta-analysis. , Gynaecological Oncology, 168, 2023, p8 - 16Journal Article, 2023, URL
• Batog, WI, Maguire P, O'Toole SA, Norris L, Abu Saadeh F, Identification of groin node metastasis in squamous vulval cancer using pre-operative [18F] FDG-PET/CT. Can unnecessary lymphadectomy be prevented?, International Journal of Gynaecological Cancer, European Society for Gynaecological Oncology, Berlin, October 2022, 32, (Supplement 2), 2022, pp1590 - 1590Conference Paper, 2022
• Ward MP, Ibrahim E, O'Toole S, Gleeson N, Abu Saadeh F, O'Donnell D, Norris LA, Thrombomodulin as a marker for VTE following neoadjuvant chemotherapy, Thrombosis Research, International Congress on Issues in Thrombosis in Cancer , Bergamo, Italy, May 2022, 213, ((6) Supplement 2), Elsevier, 2022, ppS13 - S14Conference Paper, 2022, URL
• Ward MP, O'Toole SA, Abu Saadeh F, Marchocki Z, Ibrahim EM, Martin F, Gleeon N, O'leary JJ, Norris LA, Mechanisms of cancer associated thrombosis in gynaecological cancer patients- tumour or treatment effect?, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, London, July 2022, 6, (Supplement 2), Wiley, 2022, ppPB0752 - PB0752Conference Paper, 2022, URL
• Ward MP, Lochrin SE, Ovarere C, O'Gorman C, Kane LE, Mohamed BM, Bates M, Kelly TE, O'Connor R, Kennedy J, Cadoo K, Kamran W, Beirne J, Abu Saadeh F, Martin CM, Norris LA, O'Toole SA, O'leary JJ, Platelets and immune call cloaking of circulating tumour cells in breast and ovarian cancer, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, London, July 2022, 6, ((supplement 2)), Wiley, 2022, ppPB0931 - PB0931Conference Paper, 2022, URL
• Thrombosis Update, (2020), Lucy Norris, [eds.]Journal, 2020
• European Journal of Gynaecological cancer, Elsevier, [eds.], 2020-2030Editorial Board, 2020
• Lucy A Norris, Feras Abu Saadeh, "Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis": Comment . , Journal of Thrombosis and Haemostasis, 21, (6), 2023, p1681 - 1683Journal Article, 2023
• Norris LA, Weldon S, Nugent A & Roche HM , LPS induced tissue factor expression in the THP-1 monocyte cell line is attenuated by conjugated linoleic acid, Thrombosis Research, 117, 2006, p475 - 480Journal Article, 2006
• Brosnan JF, Sheppard BL, Norris LA, Haemostatic activation in post menopausal women taking low dose hormone therapy: less effect with transdermal administration?, Thrombosis and Haemostasis, 97, (4), 2007, p558 - 565Journal Article, 2007, DOI
• Norris L A, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M , INHIBITORS AND ACTIVATION MARKERS OF THE HAEMOSTATIC SYSTEM DURING HORMONE THERAPY: , Thrombosis and Haemostasis, 100, (2), 2008, p253 - 260Journal Article, 2008
• Hellgren M, Conard J, Norris L, Kluft C, Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone, Maturitas, 62, 2009, p287 - 293Journal Article, 2009, DOI
• Kelly LA, O'Leary JJ, Seidlova-Wuttke D, Wuttke W, Norris LA, Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens, Thrombosis and Haemostasis, 104, (6), 2010, p1083-1289Journal Article, 2010, TARA - Full Text
• Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducrée J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O'Leary J, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011Journal Article, 2011, DOI , URL , TARA - Full Text
• Ismail SK, Norris L, Muttukrishna S, Higgins JR, Thrombin generation post elective caesarean section: Effect of low molecular weight heparin., Thrombosis research, 130, (5), 2012, p799 - 803Journal Article, 2012, DOI
• Brosnan JF, Sheppard BL, Kelly LA, O'Leary JJ, Norris LA, Norethisterone acetate alters coagulation gene expression in vitro in human cell culture., Thrombosis research, 131, (1), 2013, p72 - 77Journal Article, 2013, DOI
• Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103Journal Article, 2013, DOI , TARA - Full Text
• Kelly LA, Seidlova-Wuttke D, Wuttke W, O'Leary JJ, Norris LA, Estrogen receptor alpha augments changes in hemostatic gene expression in HepG2 cells treated with estradiol and phytoestrogens. , Phytomedicine , 21, (2), 2014, p155 - 158Journal Article, 2014, URL
• Abu Saadeh F, Norris L, O'Toole S, Gleeson N, Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival., European Journal of Obstetrics & Gynecology and Reproductive Biology , 170, (1), 2013, p214 - 218Journal Article, 2013
• Abu Saadeh, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N, Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk., Thrombosis Research, 132, 2013, p627 - 634Journal Article, 2013, DOI
• Ismail SK, Norris L, O'Shea S, Higgins JR, Weight-adjusted LMWH Prophylaxis Provides More Effective Thrombin Inhibition in Morbidly Obese Pregnant Women, Thrombosis Research, 134, (2), 2014, p234 - 239Journal Article, 2014, DOI
• Abu Saadeh F, O'Toole S, Gleeson N, Norris L, Peak ant-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post surgery, Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer, , Bergamot Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014Published Abstract, 2014
• Ibrahim N, Norris L, O'Toole S, Gleeson N, The effect of LMWH (tinzaparin) post surgery in gynaecological patients: a study of ant-Xa activity levels., Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, pps204-Published Abstract, 2014
• Ibrahim N, Norris L, Nikolov N, Gleeson N, Thromboelastography as a tool for detecting hypercoagulability in gynaecological cancer patients undergoing surgery, Thrombosis Research, 7th International Conference on Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014Published Abstract, 2014
• Abu Saadeh F, Norris L, O'Toole S, Langhe R, O'Leary JJ, Gleeson N., Does tissue factor and tissue factor pathway inhibitor over-expression play a role in the development of venous thromboembolism in ovarian cancer patients?, Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, ((Suppl 1)), Elsevier, 2012, pp170-Published Abstract, 2012, URL
• Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, O' Leary. J, Gleeson. N. , Why is venous thromboembolism is a common complication of ovarian cancer? , International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society. , Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE247-Published Abstract, 2012
• Abu Saadeh F, Norris L, O'Toole S, Langhe R, Gleeson N., Procoagulant activity in patients with gynecological malignancies and the effect of neoadjuvant chemotherapy , Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, (Suppl 1), Elsevier, 2012Published Abstract, 2012, URL
• Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N., ETP as a marker for venous thromboembolism in gynaecologial cancer patients post surgery, International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE249-Published Abstract, 2012
• Abu Saadeh. F, Norris. L, O' Toole, Gleeson. N., Assessing the risk and mortality of venous thromboembolism in ovarian cancer., International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE246-Meeting Abstract, 2012
• Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S, A novel serum microRNA panel to discriminate benign from malignant ovarian disease, Cancer Letters, 356, ((2ptB)), 2015, p628-636-Journal Article, 2015, DOI

• Brosnan JF, Norris LA, Sheppard BL, Effects of the menopause on circulating adhesion molecules, 2001, pp360-Meeting Abstract
• Norris LA, Bonnar J, Platelet activation in oral contraceptive users may be prevented in vitro by low dose aspirin, Irish Journal of Medical Science, (Supplement II), 1993Meeting Abstract
• Norris LA, Devitt M, Bonnar J, Fibrinolytic activation and inhibition in women using new low dose oral contraceptives, Fibrinolysis, 6, (Supplement 2), 1992Meeting Abstract
• Norris LA, Sheppard BL, Bonnar J, Whole blood platelet activation in normal pregnancy, Irish Journal of Medical Science, 160, 1990, pp358-Meeting Abstract
• Norris LA, Carroll ME, Bonnar J, In vitro aspirin inhibition of platelet activation in oral contraceptive users and controls, Irish Journal of Medical Science, 159, 1989, pp98-Meeting Abstract
• Norris LA, Carroll ME, Bonnar J, Effect of triphasic oral contraceptives on whole blood platelet aggregation, Irish Journal of Medical Science , 157, 1988Meeting Abstract
• Daly L, Norris LA, Carroll ME, Bonnar J, Effects of new oral contraceptives containing gestodene and desogestrel on fibrinolysis, Fibrinolysis, 1, 1988, pp161-Meeting Abstract
• Lucy Norris, Can we predict VTE in gynaecological cancer?, Irish Society for Gynae-Oncology (ISGO) annual scientific meeting 'TRANSLATION AND INNOVATION'., Dublin, December 1st , 2016, ISGOInvited Talk
• Lucy Norris, Prediction and Prevention of venous thromboembolism in Gynaecological cancer. , Master class in Cancer and Thrombosis, Dublin, July 7, 2015, 87-Invited Talk
• Lucy Norris, HRT and haemostasis, UCC Obstetrics and Gynaecology, research seminar, Cork, February, 2011, UCC, 87-Invited Talk
• Lucy Norris, Hormones and the risk of thrombosis., Update on Coagulation, Dublin, March, 2010, National Centre for Coagulation and Hereditary disorders, 87-Invited Talk
• Norris Lucy A, Biomarkers for cancer associated venous thromboembolism, Hospital Professional News, 2023Review Article, URL
• Brosnan J, Sheppard BL, Norris LA, Differential effects of transdermal and oral estradiol/norethisterone acetate hormone therapies on coagulation and fibrinolytic markers, Journal of Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Geneva, July 2007, 5, (Suppl 2), 2007, pp0-S-050 - 0-S-050Meeting Abstract
• Brosnan J Sheppard, BL, Norris LA, Sex steroids used in hormone treatment alter coagulation gene expression, Journal of Thrombosis and Haemostasis, International society on thrombosis and haemostasis, Geneva, 2007, 5, (Suppl. 2), 2007, ppP-S-626-Meeting Abstract
• Kelly L, O'Leary J, Wuttke W, Norris L. , Effects of Genistein versus Oestrogen on haemostatic gene expression in ovariectomised rats, Journal of Thrombosis and Haemostasis , International Society for Thrombosis and Haemostasis, Boston, July 2009, 7 , (Supplement 2), 2009, ppPP-WE-3731-Meeting Abstract
• Abu Saadeh F, Norris L, O'Toole S, Gleeson N. , The role of tissue factor and tissue factor pathway inhibitor in ovarian cancer, Thrombosis Research, Womens Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl 3), Elsevier, 2011, pp149 - 149Meeting Abstract
• SK Ismail, Norris LA, Muttukrishna S, Higgins JR, Effect of LMWH prophylaxis on thrombin generation post caesarean section, Thrombosis Research, Women's Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl), 2011, ppS137 - S137Meeting Abstract
• Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014Published Abstract
• Lynne Kelly, Shanthi Muttukrishna, Lucy Norris, John Higgins, Placental expression of haemostatic and angiogenic markers in preeclampsia, Hydrometallurgy, 1, (3), 2011, pp277-Published Abstract

The role of coagulation proteases and platelets in the aetiology of gynaecological cancers. Development of risk models for the prediction of thrombosis in gynaecological cancer patients. The effect of chemotherapy in natural anticoagulant pathways. Aetiology of thrombosis risk in high risk pregnancy patients. Effects of oestrogens, progestogens and phytoestogens on coagulation gene expression and their role in thrombosis risk. The role of coagulation gene expression in the transition from endometriosis to clear cell cancer.

• Title

  Prediction and Prevention of venous thromboembolism in pregnancy
  Summary

  Venous thromboembolism remains the leading cause of maternal morbidity and mortality. Delayed diagnosis, inadequate treatment and inadequate thromboprophylaxis account for the majority of deaths associated with this disease. Pharmacokinetics studies are required in specific groups of pregnant women receiving LMWH prophylaxis in order to devise effective evidence based dosing strategies. The recent triennial report indentified obese pregnant women and women post caesarean section, as two groups particularly at risk and where further work is required. This study will (1) investigate thrombin activity as a potential predictive tool for venous thromboembolism in pregnancy using the SCOPE study cohort (2) study the full anticoagulant (anti-IIa and anti-Xa) profile of obese pregnant woman and women post caesarean section receiving LMWH prophylaxis.
  Funding Agency

  Anu Research Fellowship/Leo Laboratories
  Date From

  July 2009
  Date To

  July 2012
• Title

  Interrogation of the Onco-metabolome in ovarian cancer
  Summary

  The metabolic syndrome is characterised by low-level inflammation, coagulation activation and increased risk of cancer. This study seeks to interrogate the inter-linked nature of these mechanisms in ovarian cancer. The association while present in ovarian cancer patients is not well defined. The aim of this study is to assess if platelet cloaking of CTCs in obese patients with ovarian cancer, due to increased systemic inflammation is a mechanism underlying worse prognosis in these patients.
  Funding Agency

  Royal City of Dublin Hospital Trust
  Date From

  2013
  Date To

  2016
• Title

  Thromboelastography as a predictor of venous thrombosis in gynaecological oncology patients undergoing surgery.
  Summary

  Ovarian cancer is associated with high rates of venous thromboembolism (VTE) particularly after surgery even in the setting of appropriate prophylaxis.The treatment and prevention of VTE is challenging in these patients after major surgery, as pelvic surgery itself is also an additional high risk factor for VTE. Thromboelastography(TEG) is a technique which allows rapid global assessment of haemostatic/fibrinolytic function and has been proposed as a marker of hypercoagulability in a variety of clinical settings. The aim of this study is to determine the level of hypercoagulability using TEG in patients undergoing major gynaecological surgery for suspected cancer, and to determine the potential of TEG as a predictor of VTE.
  Funding Agency

  Gynaecological Cancer Fund, SJH
  Date From

  2012
  Date To

  2015
• Title

  A comparative study of the effects of oral (estradiol 1mg/0.5mg norethisterone acetate) versus transdermal (estradiol 25µg/125µg norethisterone) on haemostatis in healthy post menopausal women
  Summary

  HRT is known to cause changes in coagulation and fibrinolytic gene activation which may explain the increased risk of thrombosis associated with these combinations. If these preparations are taken transdermally, the liver first pass effect is avoided and this may reduce their effects on coagulation and fibrinolytic activity. The aim of this study is to investigate the role of the route of admiminstration on the effects of HRT on haemostasis. Levels of coagulation and fibrinolytic activators and inhibitors will be measured in a group of healthy post menopausal women taking a transdermal preparation compared with a group taking an oral preparation
  Funding Agency

  Novartis
  Date From

  2002
  Date To

  2005
• Title

  Activated protein C pathway in ovarian cancer -a novel prognostic marker?
  Summary

  Development of preliminary findings investigating the role of aPC pathway in the aetiology of ovarian cancer
  Funding Agency

  TCD
  Date From

  Dec 2021
  Date To

  Dec 2022
• Title

  Lymph node status and coagulation biomarkers as predictors of venous thromboembolism in gynaecological cancer
  Summary
  Funding Agency

  Leo Pharma
  Date From

  2020
  Date To

  2022
• Title

  Phytoestogens as an alternative to HRT: assessing thrombotic risk in cell and animal models
  Summary

  The aim of this study is to examine the molecular effects of phytoestrogens on the molecular determinants of thrombus formation in both cell and animal models. By understanding these effects we may be able to assess the potential of these compounds as oestrogen alternatives with less thrombotic risk.
  Funding Agency

  HRB
  Date From

  2007
  Date To

  2010
• Title

  THE ROLE OF TISSUE FACTOR IN THE TRANSITION FROM ENDOMETRIOSIS TO CLEAR CELL CANCER OF THE OVARY
  Summary

  Increased expression of both PAR-2 and TF in the eutopic and ectopic endometrium from women with endometriosis compared with normal women has been reported (Krikun et al,2008) however it is unknown whether a further increase in expression is implicated in malignant transformation of endometrioma into clear cell cancer. Our hypothesis is that expression and activation of the TF-VIIa-PAR-2 signalling pathway is further increased in clear cell cancers particularly those formed on a background of endometriosis and that this may provide a potential target for treatment of clear cell cancers. We also believe that TFPI-2 may be a useful diagnostic marker for clear cell cancers. The aim of the study is to compare the expression of TF, VIIa and PAR-2 in clear cell cancers with endometrial tissue from patients with endometriosis. A secondary aim is to investigate the role of serum TFPI-2 as a possible non invasive tool for distinguishing endometriosis from clear cell cancers.
  Funding Agency

  Leo pharma
  Date From

  2014
  Date To

  2016
• Title

  Towards increased awareness and understanding of the risk of thrombosis in gynaecological cancers
  Summary

  A recent survey of patients who suffered a thrombosis during their cancer journey showed that, generally, patients are not warned about the risk of clots during cancer and are not told what to look out for. In addition research by our group has shown that only 45% of gynaecologists in Europe are using the correct guidelines for thrombosis prevention. The aim of this project is to increase awareness among patients regarding thrombosis and to provide an opportunity for knowledge exchange between gynaecologist and scientists working in the area
  Funding Agency

  HRB
  Date From

  January 2016
  Date To

  March 2017
• Title

  A risk model for prediction of venous thromboembolism in gynaecological cancer patients post surgery
  Summary

  Venous thromboembolism (VTE) is a common cause of death in patients with solid tumours. Cancer itself causes a hypercoagulable state, in addition chemotherapy and surgery enhance the risk. Gynaecological cancers have been associated with high rates of VTE which is excacerbated by pelvic surgery and chemotherapy. A recent study in our centre showed that one third of VTE in ovarian cancer patients occurs within 5 days of surgery despite heparin prophylaxis. Recently, clinical risk models have been developed to predict VTE in patients undergoing chemotherapy, these models have been shown to be more powerful when combined with haemostatic biomarkers. Thrombus formation is complex in cancer and is thought to result from a release of procoagulant material from the tumour combined with damage to the endothelium as a result of chemotherapy and surgery. Global tests of hypercoagulability which capture these effects are therefore attractive as determinants of thrombotic risk. Calibrated automated thrombograpy (CAT) is a recently developed global test which measures thrombin generation in plasma. Increased thrombin generation is predictive of VTE in a variety of clinical settings. The overarching aim of this project is to develop and validate a specific risk scoring model for VTE risk in gynaecological cancer patients using a combination of easily available clinical and laboratory parameters and haemostatic biomarkers. In a large population of gynaecological cancer patients, we will identify the key risk factors for VTE and use them to derive a risk score model. Based on our pilot data, we believe that a thrombin generation test may be a useful biomarker for VTE in gynaecological cancer. By understanding the mechanisms by which gynaecological cancer increases procoagulant activity, we will optimise a specific thrombin generation assay which when combined with the derived risk score model will accurately identify gynaecological cancer patients at high risk of VTE.
  Funding Agency

  HRB
  Date From

  2013
  Date To

  2017
• Title

  Thrombomodulin as a predictor for chemotherapy associated venous thromboembolism
  Summary
  Funding Agency

  TCD faculty of Health Sciences Dean's Research initiative
  Date From

  January 2023
  Date To

  January 2024
• Title

  THE ROLE OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR IN OVARIAN CANCER
  Summary

  Tissue Factor (TF) is a potent trigger of the coagulation cascade which is normally released following vascular injury. In normal tissue, TF expression is restricted to extravascular sites however recent evidence has shown that tumour cells can constitutively express TF leading to thrombin and fibrin formation on the cell surface. This activation of the coagulation system has been shown to be related to survival and is also implicated in the increased venous thromboembolic (VTE) risk in cancer patients. Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signalling activities. TFPI exhibits anti-angiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumour associated TFPI have been shown to significantly reduce tumour cell induced activation and lung metastasis. Ovarian cancer is the leading cause of death from gynaecological malignancy. The lifetime risk of developing the disease is now estimated at 1 in 59. Ovarian cancer is known to display a particular association with VTE with reports of up to 14% of patients with clear cell carcinoma of the ovary developing thromboembolic complications. In addition, patients undergoing chemotherapy have an enhanced risk of vascular thrombosis which varies among different chemotherapeutic regimens. VTE is a life threatening condition and its management is challenging in these patients who often undergo major pelvic and abdominal surgery and receive combination chemotherapy. The pathological and cellular mechanisms underlying this thrombogenic risk in cancers are not fully understood. The aim of this study is to determine the role of TF and its inhibitor TFPI in the progression of ovarian cancer and to assess their potential as predictive tools for venous thrombosis in ovarian cancer patients during treatment.
  Funding Agency

  St. James's Hospital Gynae Oncology Fund
  Date From

  2010
  Date To

  2012
• Title

  An Investigation into the in vitro effects of oestradiol and norethisterone on coagulation and fibrinolytic gene expression
  Summary

  Although it is established that hormone preparations can alter coagulation and fibrinolytic activity, the mechanism for this and its relation to increased cardiovascular risk in hormone users is unclear. The aim of this study is to investigate the in vitro effects of estradiol and norethisterone on the expression of coagulation and fibrinolytic genes in cell culture. Using TaqMan PCR and low density arrays, the direct and indirect effects of these preparations will be investigated in endothelial and hepatocyte cultures
  Funding Agency

  TCD Obs and Gynae
  Date From

  2008
  Date To

  2011
• Title

  Endogenous thrombin potential (ETP) and microparticle tissue factor(TF) activity as markers of venous thromboembolism in gynaecological cancer patients.
  Summary

  Increased Tissue Factor from tumour cells may cause an enhanced plasma procoagulant activity ultimately resulting in VTE. The majority of these patient would have major pelvic surgery as part of their treatment, with the risk of bleeding. Endogenous Thrombin Potential (ETP) assay is a new method which has shown potential as predictor of VTE risk. The aim of the study is to compare the procoagulant activity in plasma of patients with benign and malignant ovarian tumous using the ETP assay. and to compare the procoagulant activity levels in patients following neoadjuvant chemotherapy with those undergoing surgery for primary tumours
  Funding Agency

  Leo Pharma IIS/Gynaecological Oncology Fund SJH
  Date From

  2010
  Date To

  2013

Other clinical medicine, Cardiovascular medicine and haematology, Cancer, Other health sciences,

• Irish Association of Cancer Research
• Member of International Society for Thrombosis and Haemostasis 2020
• Irish National Network for Ovarian Cancer Collaboration INNOVATION Founder member Present
• Irish Society for Gynaecological Oncology

• Member Editorial Board European Journal of Gynaecological Oncology 2021
• Member Editorial Board European Journal of Gynaecological Oncology 2021
• Member of the Editorial board of Thrombosis Research
• Member of the Editorial board of Thrombosis Research
• Member of International Society for Thrombosis and Haemostasis publications committee 2016-2020
• Member of International Society for Thrombosis and Haemostasis publications committee 2016-2020
• Co-Editor in Chief of Thrombosis Update 2019
• Co-Editor in Chief of Thrombosis Update 2019